Thursday 26 June 2014 8:35 pm

Astrazeneca knocked by US regulator drug verdict

UK pharma giant Astrazeneca was dealt a blow yesterday when US regulators knocked back its bid to gain accelerated approval for a new ovarian cancer drug. Astrazeneca’s pipeline is under particular scrutiny after chief exec Pascal Soriot boasted of a bright and innovative future while fighting off a £69bn takeover bid from US rival Pfizer last month. The firm must now submit further clinical data on the new drug.